Does Rallies show Form 4 insider transactions for INBX?

Yes. Rallies tracks INBX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is INBX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INBX. It does not provide personalized investment advice.

INBX (Inhibrx Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Inhibrx Biosciences, Inc. Common Stock (INBX) is a publicly traded Healthcare sector company. As of May 21, 2026, INBX trades at $106.96 with a market cap of $1.55B and a P/E ratio of -13.02. INBX moved +0.42% today. Year to date, INBX is +43.09%; over the trailing twelve months it is +741.70%. Its 52-week range spans $10.81 to $155.29. Analyst consensus is buy with an average price target of $277.50. Rallies surfaces INBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading INBX stock inside the company?

Recent INBX insider activity includes VIKING GLOBAL INVESTORS LP sold 308.64K, VIKING GLOBAL INVESTORS LP sold 16.32K, VIKING GLOBAL INVESTORS LP sold 25.04K, Kayyem Jon Faiz bought 18.75K, and Kayyem Jon Faiz bought 18.75K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

INBX Key Metrics

Key financial metrics for INBX
Metric	Value
Price	$106.96
Market Cap	$1.55B
P/E Ratio	-13.02
EPS	$-8.39
Dividend Yield	0.00%
52-Week High	$155.29
52-Week Low	$10.81
Volume	3
Avg Volume	0
Revenue (TTM)	$1.30M
Net Income	$-130.19M
Gross Margin	0.00%

Recent INBX Insider Trades

VIKING GLOBAL INVESTORS LP sold 308.64K (~$9.95M) on Oct 7, 2025.
VIKING GLOBAL INVESTORS LP sold 16.32K (~$526.16K) on Oct 7, 2025.
VIKING GLOBAL INVESTORS LP sold 25.04K (~$807.60K) on Oct 7, 2025.
Kayyem Jon Faiz bought 18.75K (~$266.10K) on Nov 20, 2024.
Kayyem Jon Faiz bought 18.75K (~$266.10K) on Nov 20, 2024.

Latest INBX News

Inhibrx Raises Cash to $161.7M, Narrows Loss and Reveals Phase II Data — May 14, 2026
Inhibrx Shows 20% ORR and 5.5-Month PFS in Late-Line Colorectal Cancer Study — Apr 21, 2026
Inhibrx Schedules April 21 Webcast for Ozekibart CRC Phase 1/2 Update — Apr 20, 2026
Inhibrx Reports FY2025 Net Loss, $124M Cash and $75M Loan, Plans 2026 BLA — Mar 19, 2026

INBX Analyst Consensus

2 analysts cover INBX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $277.50.

Common questions about INBX

Who is trading INBX stock inside the company?: Recent INBX insider activity includes VIKING GLOBAL INVESTORS LP sold 308.64K, VIKING GLOBAL INVESTORS LP sold 16.32K, VIKING GLOBAL INVESTORS LP sold 25.04K, Kayyem Jon Faiz bought 18.75K, and Kayyem Jon Faiz bought 18.75K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for INBX?: Yes. Rallies tracks INBX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is INBX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INBX. It does not provide personalized investment advice.